• Co-founders share PLUS’s origins and future goals during television interview
• Company released child-resistant, convenient, recyclable tins cans a year before state deadline
• PLUS is working to expand its product line into cannabis-infused baked goods

The leading cannabis-edibles company in California, Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) continues to lead the way through thoughtful collaboration between experts and a constant focus on producing high-quality products. The company is dedicated to making cannabis edibles safe and approachable for the consumer.

A year ago, PLUS employees were working out of a makeshift clean room in a home garage making cannabis gum. Since then, the company has risen from number 12 in the largest cannabis-edibles market in the world to the top spot. PLUS has since relocated to a 12,000-square-foot, food-safe cannabis manufacturing facility in Adelanto, California, and it is now staffed with professional chemists and experienced food scientists. The company continues to widen the gap between itself and the competition, manufacturing three of the best-selling branded products in all product categories during Q4 2018.

Recently, PLUS co-founders Jake Heimark, CEO, and Justin Crunchington, CSO, were interviewed on Business Television (B-TV), where they shared the company’s origins, their passion behind the products and the unique responsibility they feel moving forward. Watch the full interview at http://ibn.fm/4gDeo.

“One of the hardest things to do really well when you manufacture cannabis products is to get the dosing exactly right every time,” Heimark stated in the interview. “If the product is too strong, people wind up on the couch and never want to try your product again. If the product is too weak, you don’t move at all. So getting the balance between the two is the most essential thing to the customer.”

Heimark noted that by watching long-term and short-term trends, products are created that resonate with consumers and keep them coming back for more.

As more states legalize cannabis products, PLUS is looking toward the future to identify how the company can continue to make great products for the global market in a more mature, responsible adult industry. PLUS plans to be a leader in helping others understand the benefits and the potential downsides of cannabis — and to do so responsibly.

Responsibility is a key component of the company’s values, and PLUS is leading the way in creating a safer, more responsible industry. One way in which the company is doing so is by introducing new child-resistant tins—a year before a state-mandated deadline (http://ibn.fm/qkcoN). The new tins are child-resistant, convenient and made of recyclable tinplate steel. The tins open with a press and twist, similar to a prescription medicine bottle.

In another forward move, Plus Products acquired GOOD CO-OP Inc., a California-based cannabis-infused baked goods brand, in December 2018 (http://ibn.fm/enjQ2). This acquisition will allow PLUS to expand its product line and solidify its market position. GOOD CO-OP comes with an established product line and has been featured in Vice Magazine, Fortune and Eater. The acquisition will accelerate the company’s entry into the baked edibles field, which accounts for nearly 13 percent of the cannabis-infused edibles space that is expected to become a $5.3 billion market in the next five years.

For more information, visit the company’s website at www.PlusProducts.com

• Promotion of Jason Broome to role of chief research and innovation officer is expected to bolster strategic research program targeting global markets
• Flowr grows only premium cannabis using non-irradiated production methods that generate high crop yields at low operating costs
• Global cannabis market expected to reach $154.82 billion in sales by 2026

Several strategic advancements recently announced by The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, position the company to be a world leader in crafting high-quality cannabis that appeals to a growing worldwide consumer base for the legal cannabis recreational and medicinal markets.

Jason Broome, former senior vice president of operations, has been promoted to the role of chief research and innovation officer (“CRIO”) to lead the company’s innovative research and development efforts. Broome is tasked with developing new high-quality products and will focus on Flowr’s research into cultivars, form factors and delivery systems for the global markets. He will also oversee Flowr’s state-of-the-art R&D facility, which is part of a partnership with Hawthorne Canada, a subsidiary of The Scott’s Miracle-Gro Corporation (NYSE: SMG) (http://ibn.fm/CO9XJ).

“Flowr’s product innovation portfolio must meet the world-class standards of our cultivation,” Tom Flow, co-CEO of Flowr, said in a news release announcing Broome’s promotion (http://ibn.fm/7cFNd). “It’s an unusually demanding ask, but Jason’s expertise across all aspects of product development, from molecule to market, is unique and yet totally in keeping with Flowr’s high-performance, high-creativity culture.”

Flowr’s flagship facility, an approximately 85,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols that produce high crop yields at low operating costs, enables Flowr to grow cannabis that meets Health Canada’s stringent standards while striving to avoid treating it with the taste- and smell-killing gamma irradiation that most other LP’s use to clean their product.

Canada opened up recreational cannabis to adult users in October 2018 and has since released new regulations governing cannabis-infused edibles and beverages, along with cannabis concentrates, which are set to be legalized in mid-October 2019. According to Stratistics MRC, the global cannabis market accounted for $10.39 billion in 2017 sales and is expected to reach $154.82 billion by 2026, growing at a compound annual growth rate of 35 percent during the forecast period (http://ibn.fm/WacxT).

In a career spanning more than 15 years, Broome has led the commercialization of major pharmaceutical brands; built, operated and sold several health care-related companies; and brought disruptive technologies and systems to market. Within the cannabis sector, he was co-founder of the first company licensed to cultivate and extract hemp in Kentucky and served as chief operating officer of a Colorado manufacturer of cannabidiol (CBD) oil. He holds a master’s degree in molecular genetics from the University of Ottawa.

Broome will work closely with Dr. Lyle Oberg, chief policy and medical officer of Flowr, and Dr. Deron Caplan, North America’s first cannabis cultivation Ph.D., along with celebrated Canadian chef Ryan Reed, who has been tasked with developing signature edible cannabis products for the Flowr brand (http://ibn.fm/XSBrG).

For more information, visit the company’s website at www.Flowr.ca

• hempSMART brand promoted at events surrounding Super Bowl and Oscars 2019
• hempSMART Brain has been granted a patent by the U.S. Patent and Trademark Office

Marijuana Company of America Inc. (OTCQB: MCOA) has been raising the flag for its flagship brand, hempSMART. The company ran promotions during the Super Bowl, as well as the Oscars events last month, with the goal of increasing the profile of the brand – recognition of which was already on the rise.

The hempSMART brand made appearances at multiple Super Bowl 2019 events, which included Ray Lewis’ Ray of Hope Foundation’s ‘Gold Jacket for a Purpose’ event and a special presentation at the Ice Box Club in Atlanta. The professional athletes, NFL coaches, actors, musicians and others who attended received samples of hempSMART-branded products, including hempSMART Brain and hempSMART Pain Cream. Attendees included Ray Lewis, Deion Sanders, Marshawn Lynch, Jon Stewart, Malcolm Jenkins, Von Miller, Eddie George, Adrian Peterson, Maroon 5 and the Backstreet Boys (http://ibn.fm/OEHph).

The company also promoted hempSMART products at multiple events involving celebrities that attended the 2019 Oscars. Attendees included Anthony Anderson, Craig Robinson, Emilio Rivera, Sam Rubin, Tara Reid, Viola Davis, Adrian Dev, Adina Porter, Donovan Carter, George Newbern and Travis Des Laurier. Those who attended the promotional event received a variety of CBD-infused products, including hempSMART Face, hempSMART Pain Cream and a bottle of hempSMART Full Spectrum Drops.

The U.S. Patent and Trademark Office has granted MCOA a patent for the formulation of hempSMART Brain, its flagship cannabidiol (CBD) product. hempSMART Brain is a wellness product formulated with a proprietary composition of natural ingredients and CBD for the support of brain function (http://ibn.fm/Swer5).

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

• The signature gourmet edible cannabis products will be launched in the final quarter of 2019
• Strategic hires as a part of research and development investment have been known to play a primary role in the growth of cannabis industry representatives
• Flowr Corporation has also announced the engagement of strategic communications and advisory firm ICR as part of the company’s efforts to enhance investor relations and broaden corporate communication

Canadian chef Ryan Reed will be partnering up with The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) on the development of signature edible cannabis products. The Flowr Corporation announced that it would be hiring Reed on March 1, 2019. Hiring a renowned chef enhances the already significant investment that the company has made in research and product development, Flowr Co-CEO Tom Flow said in a company news release (http://ibn.fm/mE2ub).

Ryan Reed is an Iron Chef and Chopped winner. He won the ‘Victoria Chef of the Year’ award in 2011. As part of the collaboration with Flowr, Reed will work with the company’s research and development team to create new, high-quality cannabis edibles. The products are expected to target premium clients, a market that is in line with Flowr’s brand philosophy.

The unique gourmet products are expected to be launched in the final quarter of 2019, following the anticipated legalization of edibles and infused products throughout Canada.

“Bringing Ryan into the fold is the next step in a focused R&D strategy that has created a competitive advantage for Flowr and will keep us on the cutting edge of cannabis innovation,” Flowr chief policy and medical officer Dr. Lyle Oberg said in a news release.

According to Reed, a kitchen and a cultivation facility both need leaders with technical mastery to promote innovation. Working with Tom Flow and the Flowr team is expected to result in gourmet, sophisticated edibles that will cater to the needs of the premium market, Reed concluded.

Analytical reports suggest that an investment in research and development, including strategic hires, ranks among the factors that create the most value for cannabis companies. Flowr has fully embraced this philosophy, and the latest corporate developments stand as evidence of the company’s plans for strategic growth.

Apart from announcing the partnership with Reed, Flowr Corporation has also released information about the engagement of ICR for the purpose of enhancing the company’s investor relations.

ICR is a leading strategic communications and advisory firm. ICR’s financial media expertise and extensive knowledge in the cannabis sector are expected to improve Flowr’s communication with stakeholders and investors, Flow said. In addition, ICR will be tasked with broadening the financial community’s understanding of the differentiated Flowr business model, he underlined. Over the coming six months, ICR will provide comprehensive investor relations management and corporate communication services.

The Flowr Corporation is a Health Canada licensed producer of premium cannabis products. The company was co-founded by MedReleaf co-founder Tom Flow and a team of industry pioneers. The corporation’s purpose-built cultivation facilities rank among the most advanced in the industry, resulting in high crop yield for the creation of premium and ultra-premium cannabis products.

For more information, visit the company’s website at www.Flowr.ca

• QMC recently initiated a diamond drilling project as part of its exploration program
• Results will be used to confirm and expand the Irgon Dike’s historic resource estimate
• SGS Canada to prepare an NI 43-101-compliant report

QMC Quantum Minerals Corp.’s (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) onsite geologists have reported visual confirmation of considerable spodumene mineralization within the core samples obtained from the first phase of drilling. The core is currently being logged and sampled. Once the assay results have been received from sampling of the phase one core, the company expects to greatly expand the historical published resource (1.2 million tons grading 1.51 percent Li2O) that was calculated decades ago by Lithium Corporation of Canada, a previous owner of the southern Manitoba lithium mining project.

With phase one of the drill program initiated and primarily targeting the central section of the Irgon Dike, QMC has instructed its consultant, SGS Canada, to produce, using all current and historical data, an updated resource in compliance with current NI 43-101 standards.

At least eight of the phase one drill holes have been designed to confirm the grades and widths as documented by the historic drill results. This central area of the Irgon Dike is where the historic resource of more than a million tons of lithium oxide was calculated. This historical resource was calculated over a strike length of 365 meters (1,197.5 feet) and to a depth of only 213 meters (698.8 feet), according to a news release issued on February 27 (http://ibn.fm/GX6Kt). The four remaining holes will explore the area west of the central portion of the Irgon Dike in a section coined the ‘western extension’. Drill results from these holes are expected to complement previous surface sampling and confirm the continuity of the spodumene mineralization in this direction.

As QMC has done with previous sampling programs, the company will ask for an assay analysis that reports on 56 elements. As drill holes are completed, the cores are being removed daily to a secure, off-site location for logging, cutting and sampling.

The Irgon Lithium Mine Project exploration efforts are focused on the well mineralized Irgon Pegmatite Dike, which formerly hosted a developed mine site. The project is located in southern Manitoba within a well-known pegmatite region that hosts a significant number of rare-element-bearing pegmatite dikes, including the nearby Cabot Corporation Tantalum Mining Corporation of Canada (“TANCO”) rare-element pegmatite deposit. Pegmatite is a late-stage, igneous rock that may contain significant rare-element mineralization. This is the case with respect to the Irgon Dike; spodumene, a lithium-bearing mineral which is regarded as being the preferred source of lithium, has been identified in significant quantities.

Lithium remains an important lightweight metal that plays a key role in the lithium-ion batteries that power the modern generation of computerized electronics — from small, wearable devices to larger electric vehicle batteries and still larger electrical grid temporary energy storage units. Analysis by ResearchAndMarkets.com foresees a 16.2 percent CAGR propelling the lithium-ion battery market alone to $92.2 billion in capitalization by 2024.

As SGS Canada works on bringing the Irgon Dike resource estimate up to current NI 43-101 regulatory standards, QMC is preparing for the upcoming summer field season, which will define additional diamond drill exploration to test further targets known to exist on the property.

The company announced three months ago that industry standard mobile metal ion (“MMI”) geochemical soil surveying techniques employed by SGS Canada led to the identification of new, potentially mineralized locations at the Irgon Property. MMI geochemical soil anomalies defined by the SGS survey on the northern and southern sides of the Irgon Dike could indicate buried, parallel, lithium-bearing pegmatite occurrences that don’t have surface rock outcroppings or visible ground level spodumene mineralization, according to the company (http://ibn.fm/f4oad).

QMC is also negotiating with SGS to evaluate a large pegmatite sample derived from the Irgon Dike in order to determine the best lithium recovery strategy.

For more information, visit the company’s website at www.QMCMinerals.com

• Earth Science Tech has engaged Derek Lindsay as a consultant to ensure compliance as it pursues dual listing on the Canadian Securities Exchange
• Lindsay’s areas of expertise include raising capital, strategically advising companies, cultivating investor relations and managing risk
• Cross-listing to attract new investors and capital to the company

Earth Science Tech Inc. (OTCQB: ETST), an innovative biotechnology company operating in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development, recently announced its employment of Derek Lindsay as a consultant in its pursuance of a potential dual listing of the company’s common shares on the Canadian Securities Exchange (CSE). This will be an addition to its current OTCQB listing.

Lindsay, who has helped both private and public companies in accelerating their growth, offers a diverse array of expertise areas. His knowledge (http://ibn.fm/vnSnM) includes “capital raising, strategic advice, investor relations, and risk management.” He discussed a dual listing’s ability to bring Earth Science Tech new investors and capital.

“Considering that ETST’s [research and development] division is based in Canada, cross-listing appears well-aligned with the corporate vision,” Lindsay said in a news release (http://ibn.fm/dmMAf). “Once this milestone is complete, ongoing efforts will be needed to monitor and ensure compliance, build shareholder value, and communicate with investors. I look forward to supporting the Company in these endeavors.”

Nickolas Tabraue, Earth Science Tech’s president and chairman, spoke to the effectiveness of Lindsay’s employment. “We believe Derek’s expertise makes him the perfect fit to ensure that we improve communication with our shareholders and progress on the CSE listing,” he noted. “I plan on sharing further updates as we advance this initiative.”

Earth Science Tech boasts a strong in-house team of industry experts in the fields of nutraceuticals, dietary supplements, and life sciences. Diversified, with a foothold in multiple markets, the company is passionate about making strategic partnerships and pursuing subsidiary acquisitions with the goal of becoming a world leader in the CBD sector. One such subsidiary, Canna Inno Laboratories Inc., is based out of Montreal, Canada, and provides Earth Science Tech with access to government grants. The company’s first grant has been already approved, strengthening its market presence in Canada’s recreational cannabis and CBD product industry.

For more information, visit the company’s website at www.EarthScienceTech.com

• City View Green Holdings, formerly Icon Exploration on the TSX Venture Exchange, is entering the Canadian Securities Exchange with an emphasis on new leadership
• CVGR will focus on seed-to-sale verticals in the cannabis industries as Canada’s expanding opportunities through nationwide legalization become apparent
• Highlighting the company’s potential, a master grower and founding partner of WeedMD will lead CVGR’s cultivation plan

New Canadian Securities Exchange listing City View Green Holdings Inc. (CSE: CVGR) is rapidly building an experienced leadership team as part of its aggressive efforts to become ascendant in the medicinal and adult recreational use cannabis industries.

“The cannabis space is very synergistic with the alcohol and beverage market,” CEO Rob Fia stated in a news release about the company’s team-building plan (http://ibn.fm/5nQGi). “In the end we are confident we can impress executive talent to join CVG as we set out to be a truly vertically integrated cannabis operation from seed to sale. They will see the company as the best opportunity to achieve the potential inherent in the Canadian cannabis market.”

City View Green Holdings opened on the Canadian Securities Exchange last week after moving the company, formerly known as Icon Exploration Inc., from the TSX Venture Exchange. City View Green’s new leadership includes the following:

Mario Meek, Master Grower

Mario Meek brings 10 years of networking, growing and cultivation experience in the medical cannabis industry to the City View Green team. Mario was an original founding partner of WeedMD, one of the federally licensed commercial facilities in Canada. He is currently president of 420 Consulting and has provided consulting services to Shoppers Drug-Mart, Canada’s largest pharmacy network, as well as providing numerous award-winning medical cannabis strains to licensed commercial cannabis producers. He is an experienced master grower in hydro gardens, aquaponics, aeroponics, flood and drain, ebb and flow techniques, organic grow methods and pest management techniques. He is licensed as a designated producer under the current legislation with Health Canada. Meek is experienced in every aspect of growing marijuana from seed to the finished product and has a deep understanding of the art of growing great medicinal cannabis.

Michael Hagopian, COO, Extractions

Michael Hagopian is an entrepreneur in the cannabis industry within the United States and Canada. For the past three years, Hagopian served as COO at Dose Oil, a licensed processor of cannabis extracts located in Seattle. During those years, Hagopian was responsible for building-out the facility and producing cannabis extracts that are currently available in licensed retail stores throughout the state. Hagopian developed standard operating procedures and implemented best practices for sales and production employees while also overseeing the day-to-day operations of a CO2 extraction facility in the state-regulated industry. Sales increased rapidly for Dose’s products, and it has become known for high quality and customer demand.

Prior to his relocation to Seattle, Hagopian was employed in the communications industry for 15 years as an account executive, market development representative, sales engineer and sales manager. He was employed by Comcast Communications and Time Warner Cable in South Carolina and Florida.

Yan Hai, Quality Assurance Specialist

Yan Hai is an accomplished quality assurance professional with 15 years of experience in the pharmaceutical, medical device, medical cannabis and natural health product industries. She holds a master of applied science degree in chemical engineering and applied chemistry & biomaterials and biomedical engineering from the University of Toronto. Hai has experience as a senior quality assurance consultant, quality assurance manager/specialist, quality control analyst, R&D chemist and data reviewer. She has thorough knowledge and extensive experience in quality and compliance; cGxPs; regulatory standards, including Health Canada and FDA drug, cannabis and medical device regulations; and ISO standards.

Hai currently holds a position as a senior quality assurance consultant at Innova Medipharm Inc. In her role as a senior quality assurance consultant, she carries out quality system development and improvement, auditing, inspection readiness, ACMPR/CTLS application, batch record review, deviation and complaint investigation and method validation. She has successfully conducted a GMP auditing project for ABcann Medicinals Inc. — a well-known licensed medical cannabis producer. Yan brings with her many transferrable skills, such as experience with quality systems, auditing, batch record review, method transfer and validation, microbiology, chemical testing and sampling techniques.

For more information, visit the company’s website at www.CityViewGreen.ca

• City View Green Holdings has completed a move to the Canadian Securities Exchange to boost its worldwide potential for cannabis production
• CVGR will focus on growing high-quality flower in the pursuit of creating top-notch extracts for edibles, distillates and water-soluble products
• The company has acquired the professional experience of a master grower who formerly founded a TSX Venture Exchange-listed cannabis issuer

City View Green Holdings Inc. (CSE: CVGR), a company focused on establishing a diverse portfolio as it assesses entities in the cannabis space for potential acquisition, is crafting a formidable strategy for world markets in which medicinal and adult recreational use cannabis have been granted legal acceptance.

City View Green, on March 5, 2019, opened on the Canadian Securities Exchange as part of a broader effort to move the company, formerly known as Icon Exploration Inc., from the TSX Venture Exchange to a location where it can better grow according to its vision of producing high-quality edible products, distillates and water-soluble brands, including those for the cannabidiol (CBD)-infused beverage market.

“Moving to the CSE market was strategic for our company as we believe it gives us greater flexibility to pursue opportunities around the world in various jurisdictions where cannabis is increasingly becoming legal,” CEO Rob Fia stated in a news release (http://ibn.fm/bp8TJ).

The company is completing a review of several CEO candidates as part of its new identity. The company’s website states that elements of its developing plan include:

• The company’s focus will be to grow high-quality flower and to create superior extracts. CVGR has secured an expert extraction team having worked in the Seattle market over the last three years.
• CVGR has secured a master grower formerly with a top publicly listed cannabis issuer listed on the TSX Venture Exchange.
• The company will produce high-quality medicinal products and recreational cannabis products for the adult-use market. The future in cannabis is in recreational cannabis products. Once legalized, the company is well positioned to produce high-quality edible products, distillates and water-soluble product for the beverage market.
• CVGR is currently interviewing top talent from the alcohol and beverage industry for the CEO role.
• The company’s subsidiary owns a 19.9 percent stake in a private retail-focused cannabis company with access to retail store licenses in Alberta and other retail opportunities across Canada, securing shelf space and distribution for City View Green Holdings’ products.

CVGR is an applicant for Canada’s licensed producer designation and expects to complete a 40,000-square-foot cultivation facility near Toronto for pharmaceutical-grade cannabis once the government green lights the application. Another 4.3 acres at the location is being held for possible exponential upscaling with an additional 125,000 square feet of farm and extraction facilities.

For more information, visit the company’s website at www.CityViewGreen.ca

• Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds
• The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods
• Its DehydraTECH technology has potential applications for nicotine absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Its DehydraTECH drug delivery platform fosters healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. The company’s process changes the way edible cannabinoids enter the body (http://ibn.fm/CB41E). A drug delivery innovator, Lexaria Bioscience is headquartered in Kelowna, British Columbia.

Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://ibn.fm/CsUCz). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via smoking.

The DehydraTECH platform masks taste, lessens the time of onset and increases bio-absorption by 5-10 times. The technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. Lexaria has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. These patents apply to manifold consumer/pharma product dosage forms and include food liquid emulsions, capsules, tablets and more.

The Lexaria Hemp Co. holds exclusive international rights to the Lexaria patent portfolio related to hemp-based applications. Moreover, its Canadian subsidiary, Lexaria CanPharm Corp., owns exclusive international rights to Lexaria’s intellectual property that’s applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in those global geographic areas where it is permissible to do so (http://ibn.fm/d2roZ).

Lexaria Bioscience’s business model involves developing and out-licensing its DehydraTECH platform to third-party partners/distributors (http://ibn.fm/Bx1uI). In addition, its business model involves the sale of Lexaria-developed and joint venture products. The company’s product sales include hemp oil-based CBD (cannabidiol) offerings. Its TurboCBD hemp oil capsules contain ginseng and ginkgo to promote better focus and memory and have been evaluated in clinical tests.

Lexaria’s product sales additionally include ViPova-branded premium teas. These teas deliver cannabidiol in a number of flavors and have been available for several years, showcasing Lexaria’s leadership position in beverage formulations.

Lexaria Bioscience has a collaborative research agreement with Canada’s National Research Council. This research agreement is to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions (http://ibn.fm/UP5RO).

Lexaria Bioscience has engaged in research regarding the use of its technology for nicotine absorption, relating to the nicotine industry. It has partnered, via wholly owned subsidiary Lexaria Nicotine LLC, with one of the world’s largest tobacco companies to drive innovation in oral, reduced risk nicotine consumer products using the patented DehydraTECH drug delivery platform (http://ibn.fm/IHDmy). Lexaria Nicotine aims to perform a wide-ranging series of clinical investigations of oral forms of nicotine delivery, funded by its partner, employing Lexaria’s patented DehydraTECH technology.

Lexaria Bioscience continues its R&D for the improved delivery of bioactive compounds. The company offers investors the potential to earn ROI from its disruptive technology in the emerging market of low cost edibles. Lexaria continues to advance its technology that enables consumer benefits and the lowest cost-per-serving.

For more information, visit the company’s website at www.LexariaBioscience.com

• The company has announced an increase in the potency of its lead immunotherapy candidate, Bria-IMT, through cryopreservation
• The frozen formula simplifies logistics and makes it possible for the immunotherapy to reach patients across long distances without a compromise in the safety or efficiency of the treatment
• The same cryopreservation approach will be utilized in the case of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy for advanced breast cancer

The use of a novel Bria-IMT frozen formulation is one of the exciting new developments that BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) announced recently. Bria-IMT is the company’s lead immunotherapy candidate. It is a novel treatment that works by providing breast cancer antigens that directly stimulate T-cell activity and boost the immune system’s cancer-fighting capabilities in advanced breast cancer patients.

According to BriaCell President and CEO Dr. William Williams, the freezing of Bria-IMT in a viable form through the use of well-established cryopreservation technologies enables the creation of a much more potent immunotherapy than the previous version. Apart from resulting in a more powerful formulation, the cryopreservation of Bria-IMT also enables easier management of logistics processes that make the delivery of the immunotherapy to breast cancer patients possible. Because of the combined benefits, the development of the frozen formulation can be considered a big plus for the program, and it will be the one that BriaCell will be using going forward, Williams said in an interview (http://ibn.fm/KSPa5).

Cryopreservation simplifies the storage of ready-to-inject Bria-IMT. Once delivered to a clinical facility, the formulation will simply need to be thawed prior to patient administration. In the long run, this frozen formulation is expected to reduce the per-dose cost in comparison to the old Bria-IMT delivery and administration model.

Williams explained in a news release that preparation of Bria-IMT through the previous approach was cumbersome and complex. Through cryopreservation, the viability of the formulation is better preserved than that of the previous version. Bria-IMT can be transported to distant locations in its frozen state, without any compromise in its safety or effectiveness.

The new frozen formulation technology is also applicable to Bria-OTS – BriaCell’s off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS is currently being developed and is expected to enter the clinic in the latter half of 2019.

Information about the new formulation and additional findings pertaining to the Bria-IMT clinical trials are expected to be announced during several industry events over the course of 2019.

BriaCell Therapeutics Corp. Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit, which will take place in Paris on March 21-22, 2019. The summit’s theme for 2019 is rediscovering novel approaches toward a cure for breast cancer and women’s health (http://ibn.fm/zbzMJ).

BriaCell Therapeutics Corp. will also be presenting a poster at the prestigious American Association of Cancer Research’s (“AACR”) annual meeting that will be taking place from March 29 to April 3, 2019, in Atlanta, Georgia.

These presentations will summarize results and comprehensive data analysis of the completed phase I/IIa monotherapy trial of Bria-IMT in advanced breast cancer. The monotherapy study involved 23 advanced breast cancer patients. So far, Bria-IMT’s safety has been established, and the lead candidate has achieved proof of concept in terms of expected efficacy in certain patient populations.

For more information, visit the company’s website at www.BriaCell.com